BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seillier A. The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials. Neurosci Lett 2021;759:136064. [PMID: 34146641 DOI: 10.1016/j.neulet.2021.136064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Zainab A, Shabbir D, Waqar K, Mehmood A. Consumption of Cannabis: A Risk Factor or a Therapeutic Agent for Patients with Schizophrenia. Cognizance of Schizophrenia:: A Profound Insight into the Psyche 2023. [DOI: 10.1007/978-981-19-7022-1_15] [Reference Citation Analysis]
2 Salehi A, Namaei P, TaghaviZanjani F, Bagheri S, Moradi K, Khodaei Ardakani MR, Akhondzadeh S. Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. Psychiatry Res 2022;316:114737. [PMID: 35917650 DOI: 10.1016/j.psychres.2022.114737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Jenkins BW, Buckhalter S, Perreault ML, Khokhar JY. Cannabis Vapor Exposure Alters Neural Circuit Oscillatory Activity in a Neurodevelopmental Model of Schizophrenia: Exploring the Differential Impact of Cannabis Constituents. Schizophrenia Bulletin Open 2022;3. [DOI: 10.1093/schizbullopen/sgab052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zuccoli GS, Brandão-teles C, Vieira GM, Gomes FV, Crunfli F. Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-3-030-97182-3_7] [Reference Citation Analysis]